Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-Specific Immunotherapy for Nasopharyngeal Carcinoma
NCT00834093Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2009
- Primary completion
- Mar 2012
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of Epstein-Barr virus specific cytotoxic T lymphocytes in nasopharyngeal carcinoma (NPC), sponsored by Dana-Farber Cancer Institute. Started Apr 2009; status: completed.
02
Drugs
Epstein-Barr virus specific cytotoxic T lymphocytes
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00834093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00834093.